Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics

Pharmacotherapy

Volumn 16, Issue 5 I, 1996, Pages 915-923

  Klamerus, Karen J ^a   Parker, Vernon D ^a   Rudolph, Richard L ^a   Derivan, Albert T ^a   Chiang, Soong T ^a  

^a WYETH AYERST RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DESVENLAFAXINE; DRUG METABOLITE; VENLAFAXINE;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; GENDER; HEADACHE; HUMAN; MALE; NAUSEA; PHARMACOKINETICS; VERTIGO; XEROSTOMIA;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CYCLOHEXANOLS; FEMALE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS;

EID: 0029785805     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM. Biochemical, neurophysiological and behavioral effects of Wy-45,233, and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 1991;23:191-9.
2. Haskins JT, Moyer JA, Muth EA, Sigg EB. DMI, Wy-45,030, Wy-45,881 and ciramadol inhibit locus ceruleus neuronal activity. Eur J Pharmacol 1985;115:139-46.
3. Muth EA, Haskins JT, Moyer JA, Husbands GEM, Nielsen ST, Sigg EB. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986;35:4493-7.
4. Klamerus KJ, Maloney KA, Rudolph R, Sisenwine SF, Jusko WJ, Chiang ST. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 1992;32:716-24.
5. Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed. New York:Marcel-Dekker, 1982.
6. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. Philadelphia: Lea & Febiger, 1980:128.
7. Jusko WJ. Pharmacokinetics of capacity-limited systems. J Clin Pharmacol 1989;29:488-93.
8. Metzler CM, Elfring GL, McEwen AJ. A package of computer programs for pharmacokinetic modeling. Biometrics 1974;30:562-3.
9. Jusko WJ. Guidelines for collection and analysis of pharmacokinetic data. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring, 2nd ed. Spokane, WA: Applied Therapeutics, 1986:9-54.
10. Klockowski PM, Levy G. Kinetics of drug action in disease states. XXIV. Pharmacodynamics of diazepam and its active metabolites in rats. J Pharmacol Exp Ther 1988;244:912-18.
11. Small GW. Psychopharmacological treatment of elderly demented patients. J Clin Psychiatry 1988;49(suppl):8-13.
12. Salzman C. Geriatric psychopharmacology. Annu Rev Med 1985;36:217-28.
13. Jenike MA. Psychoactive drugs in the elderly: antipsychotics and anxiolytics. Geriatrics 1988;43:53-65.
14. Goodnick P, Gershon S. Chemotherapy of cognitive disorders in geriatric subjects. J Clin Psychiatry 1984;45:196-209.
15. Robinson DS, Davis JM, Nies A, et al. Aging, monoamines and monoamine oxidase levels. Lancet 1972;1:290-1.
16. Horita A. Neuropharmacology and aging. In: Roberts J, Adelman RC, Cristatalo VJ, eds. Pharmacological intervention in the aging process. New York: Plenum Press, 1977:171-85.
17. Jenike MA. Altered drug metabolism. In: Jenike MA, ed. Handbook of geriatric psychopharmacology. Littleton, MA: Wright-PSG, 1985:9-16.
18. Bender AD. The effect of increasing age on the distribution of peripheral blood flow in man. J Am Geriatr Soc 1965;13:192-8.
19. Schumacher GE. Using pharmacokinetics in drug therapy. VII. Pharmacokinetic factors influencing drug therapy in the aged. Am J Hosp Pharm 1980;37:559-62.
20. Papper S. Clinical nephrology. Boston: Little, Brown, 1978.
21. Brandfonbrener M, Landowne M, Shock NW. Changes in cardiac output with age. Circulation 1955;12:557.
22. Geokas MC, Haverback BJ. The aging gastrointestinal tract. Am J Surg 1969;117:881-92.
23. Bender AD, Post A, Meier JP, Higson JE, Reichard G Jr. Plasma protein binding of drugs as a function of age in adult human subjects. J Pharm Sci 1975;64:1711-13.
24. Hayes MJ, Langman MJS, Short AH. Changes in drug metabolism with increasing age: phenytoin clearance and protein binding. Br J Clin Pharmacol 1975;2:73-9.